Merck Foundation

What Merck Foundation does

Merck & Co., Inc. (operating as Merck in the United States, Canada and Puerto Rico, and as MSD in all other markets) is a publicly traded research-intensive biopharmaceutical company founded in 1891 and headquartered in Rahway, New Jersey. The company develops, manufactures, and commercializes prescription pharmaceuticals, vaccines, and animal health products across therapeutic areas including oncology, vaccines, infectious diseases, cardiometabolic and respiratory conditions, immunology, neuroscience, and ophthalmology. Flagship oncology asset KEYTRUDA (pembrolizumab), a PD-1 inhibitor, anchors the portfolio alongside vaccines GARDASIL 9, CAPVAXIVE, VAXNEUVANCE, and ERVEBO; infectious disease products LAGEVRIO, ZEPATIER, PREVYMIS, and ISENTRESS; cardiometabolic/respiratory products JANUVIA, WINREVAIR, OHTUVAYRE, and VERQUVO; and animal health products BRAVECTO and Activyl through the Merck Animal Health subsidiary. R&D operations span multiple modalities — small molecules, biologics, antibody-drug conjugates, individualized neoantigen therapies — supported by data science and AI platforms including the proprietary KERMT small-molecule lead optimization model and multimodal AI agents for drug discovery.

Merck generates revenue primarily through prescription pharmaceutical and vaccine sales via three channels: direct field sales to healthcare providers and hospitals, distribution through authorized distributor and pharmacy networks globally, and direct patient access through the MerckHelps patient assistance program. The company holds an extensive granted U.S. patent portfolio protecting its major franchises and markets through physician engagement, patient support programs, scientific conferences, and digital content including podcasts and clinical trial information. Beyond commercial operations, Merck operates the Merck for Mothers global initiative — launched in 2011 with a $500M commitment extended by an additional $150M through 2025 — that has reached 30M+ women across 75+ country sites through partnerships with organizations including PATH, Jhpiego India, FOGSI, City Cancer Challenge, Global Financing Facility, and the CDC.

Name

Merck Foundation

Legal name

Merck & Co., Inc.

Website

https://merck.com

Company type

Public

Founded year

1891

Operating status

Operating

Short description

Merck & Co., Inc. is a publicly traded research-intensive biopharmaceutical company developing prescription medicines, vaccines, and animal health products across oncology, infectious disease, cardiometabolic, and neuroscience franchises, serving healthcare providers and patients globally through direct sales, distributor networks, and patient assistance programs.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Monitoring, Evaluation, Research & Learning (MERL) (BPAGABAO), Travel & Tropical Disease Vaccines (HLAIAEAE)

Keywords

• Prescription pharmaceuticals
• Oncology immunotherapy
• Preventive vaccines
• Animal health products
• Maternal health programs

Headquarters

HQ city

Rahway

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical Products: Revenue generated from prescription medicines and vaccines sold to healthcare providers, hospitals, pharmacies, and directly to patients through patient assistance programs. Products include KEYTRUDA, vaccines, and treatments across multiple therapeutic areas.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

Merck & Co., Inc. is a research-intensive biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines, vaccines, and animal health products across oncology, infectious diseases, vaccines, cardiometabolic diseases, immunology, and rare diseases. The company's flagship products include KEYTRUDA (pembrolizumab), GARDASIL 9, CAPVAXIVE, LAGEVRIO, and WINREVAIR. It also runs the Merck for Mothers global initiative to end preventable maternal deaths.

Product overview

Merck & Co., Inc. (known as Merck Foundation in the US context) is a premier research-intensive biopharmaceutical company with a diversified portfolio of prescription pharmaceuticals, vaccines, and animal health products. The company operates across multiple therapeutic areas including oncology (KEYTRUDA), vaccines (GARDASIL 9, CAPVAXIVE, VAXNEUVANCE, ERVEBO), infectious diseases, cardiometabolic diseases, and immunology. Merck for Mothers represents the company's global social impact initiative focused on maternal health. The portfolio spans from innovative cancer immunotherapies to preventive vaccines and treatments for chronic conditions, supported by extensive R&D capabilities in data science, AI, and drug discovery.

Differentiator

Problem solved

Functional benefit

Brands

• Merck for Mothers: Global initiative to help create a world where no woman has to die while giving life, focused on advancing high-quality maternity care, harnessing innovations for maternal health, and catalyzing solutions that respond to local needs
• Merck Animal Health
• MSD

Quantifiable outcome

• 30+ million women reached with maternal health programs
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles4 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature11 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• City Cancer ChallengecoreStrategic or Co-development Partner · 15 May 2026Merck and City Cancer Challenge expanded global partnership to strengthen women's cancer care. The initiative aims to reach more than 300,000 women living with cancer around the world by 2030 through collaborative programs addressing cancer diagnosis, treatment, and care access.
• CDC (Centers for Disease Control and Prevention)coreStrategic or Co-development Partner · 1 January 2020Merck for Mothers provided funding to support CDC's Hear Her maternal health communication campaign, bringing attention to maternal mortality and providing support to pregnant and postpartum women.
• Jhpiego IndiacoreStrategic or Co-development Partner · 1 January 2017Merck for Mothers partnered with Jhpiego India and the Federation of Obstetric and Gynecological Societies of India to launch Manyata - an initiative to improve quality maternity and newborn care in private facilities through training on clinical, facility, and patient care protocols.
• Federation of Obstetric and Gynecological Societies of IndiacoreStrategic or Co-development Partner · 1 January 2017Partnership to launch Manyata initiative improving quality of maternity care in private facilities across India through standardized training and certification programs.
• Ferring PharmaceuticalscoreStrategic or Co-development Partner · 1 January 2014Merck, Ferring Pharmaceuticals, and WHO collaborated to advance heat-stable carbetocin to prevent excessive bleeding after childbirth (postpartum hemorrhage). Carbetocin remains stable at room temperature unlike oxytocin, addressing cold chain challenges in low-resource settings.
• Pledge Guarantee for HealthminorStrategic or Co-development Partner · 1 January 2013Innovative financing partnership leveraging private sector funding to speed delivery and access to life-saving health supplies including contraceptives, bed nets, and medicines. Merck and other suppliers provide up-front price discounts to aid recipients.
• Saving Mothers, Giving Life PartnershipcoreStrategic or Co-development Partner · 1 January 2012Public-private partnership focusing on helping mothers during labor, delivery, and the first 24 hours following birth. Merck committed more than $200 million to the partnership beginning with programs in Uganda and Zambia.
• PATHcoreStrategic or Co-development Partner · 1 January 2011Merck for Mothers and PATH collaborated to identify game-changing maternal health technologies, focusing on post-partum hemorrhage (PPH) and preeclampsia - the two leading causes of maternal mortality. Collaboration surfaced heat-stable carbetocin and magnesium sulfate optimization initiatives.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Amgen: Amgen is a leading biologic-products manufacturer with an oncology, inflammation, and cardiovascular portfolio, competing with Merck in biosimilars, hematology, and inflammation — making it a peer in the biologics manufacturing and specialty-pharma segments.
• Roche: Roche is a top-three oncology competitor with a parallel PD-L1 franchise (Tecentriq) directly challenging KEYTRUDA, plus a large diagnostics arm and a vaccine/infectious-disease business that mirrors Merck's therapeutic breadth.
• Sanofi: Sanofi competes across vaccines (Fluzone, pediatric combinations), specialty care, and rare disease, with Dupixent as a flagship immunology asset. Its vaccines and specialty-pharma mix directly mirrors Merck's portfolio structure.
• GSK: GSK is a direct peer in vaccines (Shingrix, Bexsero, Cervarix competing with GARDASIL 9), specialty/HIV medicines, and respiratory disease — making it the closest vaccine-to-vaccine peer to Merck's vaccine franchise.
• Pfizer: Pfizer is a global biopharmaceutical major with overlapping therapeutic areas including oncology, vaccines (including COVID-19 and pneumococcal via Prevnar), infectious diseases, and cardiometabolic therapies — directly comparable to Merck's diversified prescription-pharma and vaccine franchises.
• AstraZeneca: AstraZeneca competes with Merck across oncology (Imfinzi in immuno-oncology, Tagrisso, Lynparza), vaccines (including COVID partnerships), and rare/cardiovascular disease, with a comparable global commercial footprint and pipeline depth.
• Bristol-Myers Squibb: BMS is the most direct immuno-oncology peer via Opdivo (nivolumab), the principal PD-1 competitor to KEYTRUDA, and also competes in hematology, cardiovascular, and immunology — directly overlapping Merck's oncology and specialty-pharma core.
• Eli Lilly: Lilly competes with Merck in oncology, diabetes (parallel to JANUVIA), and immunology, with a rapidly growing cardiometabolic and obesity franchise. Comparable R&D intensity and global commercialization scale make it a relevant large-cap pharma peer.
• Novartis: Novartis is a focused biopharmaceutical peer overlapping with Merck in oncology, cardiometabolic disease (Entresto in heart failure parallels Merck's VERQUVO), and immunology — operating with a similarly diversified specialty-pharma business model.
• Johnson & Johnson: J&J's Innovative Medicine segment competes directly with Merck in oncology, immunology, and infectious disease, while J&J's MedTech and consumer health add adjacent breadth — making it a like-for-like diversified biopharmaceutical peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xtwitter.com/Merck
• YouTubeyoutube.com/user/Merck
• Facebookfacebook.com/MerckInvents
• LinkedInlinkedin.com/company/merck
• Instagraminstagram.com/merck

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Merck Foundation